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Emerging safety and efficacy data for rivaroxaban suggest traditional therapy and rivaroxaban are 3	
comparable in the morbidly obese. However, real-world data that indicate pharmacokinetic (PK) 4	
parameters are comparable at the extremes of body size are lacking. The International Society of 5	
Thrombosis and Haemostasis Scientific and Standardisation Committee (ISTH SSC) suggests 6	
avoiding the use of DOACs in patients weighing >120kg or with a BMI >40kg/m2 and gives no 7	
recommendation on the use of DOACs in those <50kg.  8	
Objectives 9	
To generate a population PK model to understand the influence of bodyweight on rivaroxaban 10	
exposure from clinical practice data. 11	
Method 12	
Rivaroxaban plasma concentrations and patient characteristics were collated between 2013 and 2018 13	
at King’s College Hospital anticoagulation clinic. A population PK model was developed using a non-14	
linear mixed effects approach and then used to simulate rivaroxaban concentrations at the extremes of 15	
bodyweight.  16	
Results 17	
A robust population PK model derived from 913 patients weighing between 39kg and 172kg was 18	
developed. The model included data from n=86 >120kg, n=74 BMI >40kg/m2 and n=30 <50kg. A 19	
one-compartment model with between-subject variability on clearance and a proportional error model 20	
best described the data. Creatinine clearance calculated by Cockcroft-Gault, with lean bodyweight as 21	







Our work demonstrates rivaroxaban can be used at extremes of bodyweight provided renal function is 1	
satisfactory. We recommend that the ISTH SSC revises the current guidance with respect to 2	




• Evidence to support the use of rivaroxaban at extremes of body weight is limited.  7	
• A population pharmacokinetic model for rivaroxaban was derived from clinic practice data.  8	
• Renal function is the most important factor to be considered when prescribing rivaroxaban.  9	
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The direct oral anticoagulants (DOACs) are increasingly prescribed for the prevention and treatment 2	
of venous thromboembolism (VTE) and for stroke prophylaxis in the context of atrial fibrillation 3	
(AF).[1] DOACs are at least as safe and effective as vitamin K antagonists for these indications, both 4	
in controlled phase III studies and post-marketing real-world studies.[2-5] However, a commonly 5	
encountered question in clinical practice is whether DOACs are safe and effective in those at the 6	
extremes of weight: <50kg and >120kg. The clinical trials of these agents did not have sufficiently 7	
large numbers of patients in the extremes of weight categories to be able to conclude that this would 8	
be the case. 9	
Evidence from traditional anticoagulants suggests that bodyweight does impact on the dose 10	
required.[6]  For example, low-molecular-weight heparin is dosed on a IU/kg basis for the acute 11	
management of VTE [7-9] and it is widely recognised that the maintenance dose of warfarin is higher 12	
in those of a higher bodyweight.[10,11] It is therefore intuitive to expect the same to be true for the 13	
DOACs. 14	
Rivaroxaban was the first DOAC to be licensed in the European Union for treatment of VTE and the 15	
first factor Xa inhibitor to be licensed for the prevention of stroke in AF. Despite its widespread use 16	
clinicians have been cautious when prescribing rivaroxaban in patients at extremes of bodyweight, 17	
due to concern that these patients may have appreciable differences in their pharmacokinetic 18	
parameters which may impact on overall drug exposure and clinical outcomes.[12]  The manufacturer 19	
of rivaroxaban states, ‘in patients who are at the extremes of weight, only a small influence of weight 20	
on patients’ rivaroxaban plasma concentrations (<25%) is observed and no dose adjustment is 21	
necessary’.[13] However, these recommendations are based on either small pharmacokinetic studies 22	
or work derived from the phase III clinical trials for rivaroxaban, with insufficient numbers of patients 23	
at the extremes of weight to allay clinicians’ concerns. 24	
In 2016 the International Society of Thrombosis and Haemostasis Scientific and Standardisation 25	





appropriate standard dosing of DOACs in patients up to 40 kg/m2 or weight <120kg for VTE 1	
prevention and treatment and prevention of ischemic stroke and systemic arterial embolism in AF, 2	
(ii)not to use DOACs in patients with a BMI >40 kg/m2 or weight >120 kg due to limited data and 3	
available pharmacokinetic/ pharmacodynamic (PK/PD) evidence suggesting decreased drug exposure, 4	
peak concentration, and shorter elimination half- lives with increasing weight, and (iii)if DOACs are 5	
used in patients with a BMI >40 kg/m2 or weight >120 kg, then to check a drug- specific peak and 6	
trough level. If the drug level is reported back within the expected range, continuation of the DOAC 7	
seems reasonable. No guidance is provided for patients with weight <50 kg.  8	
Real-world clinic population data have focused on outcomes, with most emerging data focused on 9	
high bodyweight. EINSTEIN and Xalia investigators comparing rivaroxaban and enoxaparin/warfarin 10	
found no difference between treatment arms in the rate of VTE recurrence amongst obese 11	
patients.[14,15] This has also been observed in prospective registry data and large retrospective data 12	
from the United States (US).[16-18]  13	
Conversely, outcome data for patients <50kg are limited to a subgroup analysis of the so-called fragile 14	
patients of the EINSTEIN pooled data and observational studies.[15,19] Reflecting current practice, 15	
the Registro Informatizado Enfermedad Trombo Embólica (RIETE) registry has described a tendency 16	
toward traditional anticoagulation therapies in this subgroup.[19] 17	
Barsam and colleagues have previously derived a population PK model from 101 clinic patients, 18	
which suggested that bodyweight on its own was not a significant predictor of rivaroxaban PK. 19	
However, the work was limited by the number of samples from patients in the extremes of weight 20	
categories.[20] We now present a full population PK model developed from a large number of 21	
patients attending our anticoagulation clinics. The aim was to develop a population PK model which 22	








Data were collected from King’s College Hospital Foundation NHS Trust, in South East London. 3	
Comprising two main sites, the hospital cares for an ethnically diverse, inner-city population, as well 4	
as an older adult population of Northern European descent. DOAC use began in the anticoagulation 5	
clinics during the summer of 2012, when dabigatran became available, followed by rivaroxaban in 6	
early 2013. In order to confirm the applicability of fixed dosing to all patients and gain a better 7	
understanding of the possible factors influencing drug exposure, it was standard practice locally to 8	
measure a DOAC plasma concentration during the early years of DOAC prescribing. For the purpose 9	
of this study we have retrospectively assimilated the plasma concentration data for patients prescribed 10	
rivaroxaban between June 1, 2013 – September 21, 2018. The patients included in this study were 11	
attending the anticoagulation clinic as part of routine follow up, predominantly for the prevention of 12	
stroke due to AF and the acute treatment and secondary prevention of VTE. Case notes were 13	
reviewed, with patient characteristics (age, weight, height, indication for anticoagulation, history of 14	
heart failure) and laboratory results (creatinine, bilirubin, albumin, rivaroxaban plasma concentration) 15	
collated for analysis. Creatinine clearance (CRCL) was calculated for each patient using the 16	
Cockcroft-Gault (CG) equation.[21] For the purposes of this study, this was computed using both total 17	
bodyweight and lean bodyweight in order to understand which weight descriptor was optimal 18	
(Calculations described in the Supplemental Material).[22] All subjects were eligible if they had a 19	
rivaroxaban sample drawn and a patient reported time of last dose recorded on their blood test form 20	
and/or electronic DAWN® record (anticoagulation software system).[23] Sample times for the 21	
rivaroxaban plasma concentrations were not pre-specified. 22	
One hundred and one (11%) patients have been previously described by our group, from which an 23	
early PK model was developed and are also included in this dataset.[20] The data for these patients 24	
were collected specifically for the research being undertaken between June 1, 2013- April 30, 2014 25	
from our hospital for patients prescribed rivaroxaban for VTE treatment and primary prevention 26	






Since rivaroxaban samples were collected as standard of care, no ethical approval was required. 2	
Samples from Barsam’s study were collected with ethical approval by the London Harrow Ethics 3	
Committee, REC  reference  number: 12/LO/1951 as well as the  King’s College Hospital Research 4	
and Development Department.[20] 5	
 6	
Assaying the Rivaroxaban Plasma Concentration 7	
An anti-Xa activity assay (Diagnostica Stago, Asnières-sur-Seine, France), was used to characterise 8	
the rivaroxaban plasma concentration. Following sample collection, it was centrifuged in a Rotina 420 9	
R centrifuge (Hettich Zentrifugen), double spun for 7 minutes at 2500 g and frozen within 1 hour of 10	
sample collection. The samples were stored at −40°C until analysed on the STA-R evolution analyser 11	
(Diagnostica Stago) in the laboratory at King’s College Hospital within 4 weeks. The lower and upper 12	
limits of quantification (LLOQ/ULOQ) for this assay were 20ng/mL and 500ng/mL, respectively. 13	
This anti-Xa  assay has previously been shown to correlate well when the same samples were assayed 14	
using turbulent flow liquid chromatography with high-resolution mass spectrometry.[24] 15	
 16	
Population Pharmacokinetic Modelling 17	
Population PK modelling uses data from all subjects simultaneously to characterise the concentration 18	
time-course of a drug for both the population and the individual subjects. Central tendency is used to 19	
estimate population PK parameters. The approach is recommended by both the US Food and Drug 20	
Administration and the European Medicines Agency during the drug development process and also 21	
works well in a clinical environment, where the data can be sparse.[25,26] Population PK modelling 22	
combines a mathematical and statistical approach to characterise a complex biological system. A 23	
mathematical model is used to generate population estimates for parameters such as apparent volume 24	
of distribution (Vd/F) and apparent clearance (CL/F). These estimated population values are termed 25	





describe the variance between and within individuals and to estimate residual unexplained variability 1	
(the error model). A covariate analysis is then executed to explain between-subject variability.  2	
Population PK is commonly utilised by the pharmaceutical industry to determine optimal dosing of 3	
drugs and is also used by researchers in the clinical setting. For example, population PK analysis has 4	
previously provided compelling evidence that enoxaparin could be administered once daily during the 5	
ante-natal period for the treatment of VTE.[27] 6	
 7	
Rivaroxaban Population Pharmacokinetic Model Building  8	
To develop a base model, rivaroxaban plasma concentration data were explored by applying one-and 9	
two-compartment models, with a first order input parameter. On review of the literature, two 10	
compartmental models have been described in healthy volunteers and in the paediatric setting, but 11	
they have not been successfully replicated from more sparse data.[28] 12	
Competing base models were assessed by statistical improvements in the fit of the model according to 13	
the objective function value (OFV) (computed as minus twice the log-likelihood of the data), 14	
goodness of fit plots, assessment of the precision of the parameter estimates and residual variability. 15	
Initially a first order conditional estimation with interaction method was used. The importance of 16	
sampling method was included to review the standard errors for the precision of parameter estimates. 17	
Using these criteria, a base model was identified. 18	
A proportion of the observed rivaroxaban concentrations was reported as ULOQ and LLOQ (46 19	
samples, 4.2% ULOQ and 28 samples, 2.5% LLOQ). Observations reported as ULOQ were 20	
accounted for using Beal’s M3 likelihood estimation and observations reported as LLOQ were fixed 21	
to half the LLOQ (10ng/mL) (M5 method).[29] 22	
 23	
Only covariates with mechanistic meaning were considered for analysis; age, gender, total 24	





TBW (CRCLTBW), creatinine clearance LBW (CRCLLBW), diagnosis of AF and a diagnosis of 1	
heart failure.[21,22] Covariates were initially plotted against the PK parameters random effects to 2	
identify relevant trends. Selected covariates were then added in a univariate stepwise approach to the 3	
base model. Covariates were retained if a decrease in the objective function value of >6.64 (p<0.01) 4	
was seen. A backwards elimination was then executed, whereby all covariates that had been identified 5	
as significant were added to the base model and removed singularly to evaluate their continued 6	
relevance. The covariate was considered to have continued relevance if the increase in objective 7	
function was greater than >10.83 (p< 0.001). A nonparametric 1000 replicate bootstrap procedure was 8	
carried out on both the base and final covariate models. To evaluate the final model, a visual 9	
predictive check (VPC) was generated. The VPC shows the 5th, 50th and 95th prediction intervals, 10	
simulated from the final model parameter estimates, overlaid with the 5th,50th and 95th percentiles 11	
from the observed data. A well-performing model would see the simulated data superimposed on the 12	
observed data. 13	
Finally, a 1000-replicate simulation was performed from the final model to estimate rivaroxaban 14	
concentration-time profiles based on patients at extremes of bodyweight and for those with varying 15	
degrees of renal impairment. Simulation data were then used to estimate area under the curve (AUC) 16	
and maximum concentration (Cmax) using PKNCA in R.[30] AUC and Cmax derived from the model 17	
were compared with those described in the literature. 18	
NONMEM version 7.4.2 was used for modelling and simulation, using both the first-order conditional 19	
estimation with interaction and the Laplacian estimation method (when M3 method applied to ULOQ 20	
data).[31] Perl Speaks NONMEM (version 4·8·1) (PsN), and R Studio (version 3.6.0) were used for 21	
graphical analysis, model diagnostics and for statistical summaries.[32,33] PKNCA (version 22	









A total of 913 patients contributed 1108 rivaroxaban plasma concentrations, 193 (17%) from the 2	
previous Barsam model and 915 (83%) samples from routine care in the anticoagulation clinic. The 3	
mean number of samples per patient was 1.21 (range 1-6). The characteristics of the 913 patients are 4	
outlined in Table 1.  5	
 6	
Table 1. Patient characteristics and indications for anticoagulation (n=913) 
 
Patient Characteristic N % 
Gender (%)   
Female 391  42.8 
Male 522  57.2 
Age (mean [SD])* 67.03 [15.00]  
Weight (kg) (mean [SD])*    85.75 
[23.07] 
 
Weight (kg)   
<50 30  3.3 
50-100 668  73.2 
100-120 129  14.1 
>120 86  9.4 
Lean body weight, kg (mean [SD])    55.80 
[13.10]  
 
Creatinine (umol/L) (mean [SD])    86.73 
[27.57] 
 
BMI, kg/m2 (mean [SD])*  29.67 [7.01]   





Underweight  <18.5 19  2.1 
Normal 18.5-25  231  25.3 
Overweight  25-30  282  30.9 
Obese (Class I) 30-35  185  20.3 
Obese (Class II) 35-40  122  13.4 
Obese (Class III) >40 74  8.1 
CRCLTBW, ml/min (mean [SD])* 91.47 [43.81]   
CRCLTBW, ml/min (%)   
<30 20  2.2 
30-50 132  14.5 
50-90 358  39.2 
>90 403  44.1 
CRCLLBW, ml/min (mean [SD]) 59.51 [26.71]  
CRCLLBW, ml/min (%)   
<30 128  14.0 
30-50 255  27.9 
50-90 399  43.7 
>90 131  14.3 




20mg once daily 











15mg twice daily 
20mg once daily 




















20mg once daily 
15mg once daily 









Abbreviations: BMI, Body mass index, CRCLLBW, Creatinine clearance calculated using lean 
bodyweight; CRCLTBW, Creatinine clearance calculated using total bodyweight; LBW, lean 
bodyweight; SD, standard deviation; TBW, total bodyweight; VTE, venous thromboembolism * 
Patient characteristic range; Age 19-96 years,  weight 39-172kg,	body	mass	index	16-56	kg/m2,	and	
creatinine	clearance	16-	259ml/min. †Alternative doses, 30mg once daily (x1) and 10mg twice 
daily (x4) ‡ Other indications for anticoagulation – Left ventricular thrombus, cardioembolic stroke 
















Figure 1a describes the breadth of samples in relation to the time after dose and Figure 1b illustrates 1	
the range of rivaroxaban samples taken from patients according to bodyweight, with those falling 2	
outside the ISTH SSC guideline range highlighted. Figure 1c illustrates the frequency distribution of 3	
total bodyweight. 4	
 5	
Pharmacokinetic Model Development 6	
One- and two-compartment models with different inter-individual variability and residual unexplained 7	
variability were evaluated.  A one-compartment model parameterised in terms of CL/F, Vd/F and a 8	
first-order absorption rate constant (Ka) with inter-individual variability on CL/F and a proportional 9	
error model, was the best performing base model. The estimation of CL/F was not normally 10	
distributed and so a Box-Cox transformation was applied. Dose was explored on relative 11	
bioavailability (F) as previously described in the literature, [28,34] although this did not improve the 12	
fit of the model to the data and caused model instability.  13	
The results from the 1000 bootstrap procedure demonstrated that the median and confidence interval 14	
estimates were in alignment with estimates derived from the base model (Supplemental Material).  15	
Following the development of the base model, a covariate analysis was conducted. Gender, age, 16	
TBW, LBW, albumin, bilirubin, creatinine, creatinine clearance, calculated with the CG equation 17	
using TBW and LBW, the diagnosis of AF or a documented diagnosis of heart failure were explored 18	
on CL/F. Additionally,  gender, age, TBW, LBW, albumin, and the diagnosis of AF or a documented 19	









Table 2. Univariate covariate analysis 1	
Model Covariate Covariate Relationship ΔOBV 
1_002 CL/F*(CRCLLBW/55)0.396 Power -169.376 
1_032 CRCLLBW on CL/F Emax -161.098 
1_001 CL/F*(CRCLTBW/84)0.353 Power -143.138 
1_032 CL/F*(AGE/67)-0.524 Power -99.572 
1_011 CL/F*(LBW/55)0.468 Power -52.420 
1_007 CL/F*(AF)0.808 Proportional change -44.510 
1_012 CL/F*(CR/82)-0.337 Power -40.973 
1_010 CL/F*(TBW/84)0.331 Power -32.310 
1_008 CL/F*(HF)0.804 Proportional change -28.016 
1_006 CL/F*(SEX)0.873 Proportional change -19.322 
1_004 CL/F*(ALBU/42)0.708 Power -13.815 
1_003 CL/F*(BMI/29)0.153 Power -5.481 
1_005 CL/F*(BILI/9)-0.1 Power 0.631 
1_019 Vd/F*(AGE/67)0.384 Power -15.331 
1_025 Vd/F*(AF)1.2 Proportional change -10.282 
1_024 Vd/F*(HF)1.19 Proportional change -5.249 
1_018 Vd/F*(ALBU/42)—0.705 Power -3.881 
1_026 Vd/F*(BILI/9)0.106 Power -2.897 
1_021 Vd/F*(LBW/55)-0.085 Power  -0.534 
1_020 Vd/F*(TBW/84)-0.0739 Power -0.506 
1_022 Vd/F*(BMI/29)-0.0141 Power -0.021 
1_023 Vd/F*(SEX)0.994 Proportional change -0.017 
ΔOBV represents the change from the basemodel objective function value with the addition of a 
covariate. All models minimised successfully. Gender, a diagnosis of heart failure (HF) and a 





presence of AF and HF as the factors=1. Abbreviations: AF, atrial fibrillation; ALBU, albumin; 
BILI, bilirubin; BMI, body mass index; CL/F, Apparent clearance, CRCLLBW, Creatinine 
clearance calculated using lean bodyweight; CRCLTBW Creatinine clearance calculated using 
total bodyweight, CR, creatinine; HF, heart failure; LBW, lean bodyweight, TBW, total 






















The covariate which improved the performance of the model to the greatest extent was CRCLLBW. 1	
Age, creatinine, LBW, TBW and gender were not investigated further on CL/F as they are included 2	
within the CG equation, thus confounding their influence. In the literature, bodyweight had shown to 3	
be a significant covariate on Vd/F, so this was added in addition to CRCLLBW on CL/F and the 4	
objective function showed a marked improvement (ΔOBJ function -21.92).[28] Age and AF on Vd/F 5	
were found to improve the objective function during the univariate analysis. However, during the 6	
backwards elimination they were no longer found to be significant influential covariates and were not 7	
investigated further. CRCLLBW on CL/F and LBW on Vd/F were included as significant covariates 8	




















The final model described the observed data well. Goodness of fit plots (Supplemental Material), 2	
displaying observed and individual predicted rivaroxaban concentrations, showed a trend consistent 3	
with the line of unity at lower concentrations. However, there is a trend for underestimation at higher 4	
concentrations. This has been seen within the studies from industry and has been previously attributed 5	
to the selection of a one-compartment structural model which is required with such sparse data.28,34,35  6	
A visual predictive check (VPC) for the final model is presented in Figure 2, with the shaded areas 7	
representing simulated data and the red lines representing the observed data. As described previously, 8	
we see an underestimation of the rivaroxaban concentration at high concentrations on the VPC around 9	
the median, but good agreement as plasma concentration decreases. The overall trend is well 10	
characterised by the model.  11	
The final parameter estimates are shown with the 1000 replicate bootstrap in Table 3, and represented 12	
mathematically in Figure 3. A visual predictive check for stratified by weight <120kg and 13	














Table 3 Parameter estimates from the Final Pharmacokinetic Model with Bootstrap  
Results 
 Model Estimate 1000 Bootstrap 
Parameter Estimates 95% CI Median 2.5th-97.5th 
Percentile 
CL/F (L/h) 5.57 5.34 - 5.82 5.54 5.33 – 5.80 
Vd/F (L) 59.4 54.60 – 64.20 59.3 54.6 – 64.2 
Ka (h−1) 0.707 0.552 – 0.862 0.704 0.556 – 0.858 
Shape λ  -1.830 -3.133 – -0.527 -1.707 -2.929 - -0.730 
FACCRCLLBW  0.446 0.390 – 0.502 0.449 0.388 - 0.503 
FACLBW 0.519 0.319 - 0.719 0.560 0.313 - 0.725 
ωCL, % CV 23.02 (37.9) 18.64 - 26.69 23.34 19.42 – 26.13 
Proportional error 
(%)  
46.37 (15.6) 43.96 – 48.66 46.17 43.90 – 48.63 
Objective function 
 
-4561.424    
Abbreviations: CL/F, apparent clearance; CI, confidence interval, CV coefficient of variation; 
FACRCLLBW exponent on creatinine clearance calculated using lean bodyweight on CL/F; FACLBW 
exponent of LBW on Vd/F. Ka absorption rate constant; Vd/F, apparent volume of distribution; 𝜔CL 
between subject variability on rivaroxaban clearance; Shape λ, Lambda - Box-Cox transformation 











Using the final model population parameter estimates, simulations were generated. AUC and Cmax 2	
are presented in boxplots from the simulated data in Figures 4a-4d.  The centre, lower edge and upper 3	
edge of the box represent the median, 25th and 75th percentiles. The geometric mean and range of the 4	
AUC and Cmax values described by the Einstein DVT phase II studies are plotted in red and dashed 5	
red lines respectively for comparison.[35]  6	
The median AUC was 63% higher and the Cmax 35% higher in severe renal impairment, compared 7	
with patients with no renal impairment. The median AUC and Cmax were 18% and 19% lower 8	
respectively in simulated patients of 200kg and 16% and 17% lower in simulated patients of 150kg, 9	
compared with 70kg patients. The prediction intervals overlap across all bodyweights and are in 10	
keeping with those described in the literature from the Einstein DVT phase II data.[35] 11	
Figure 4e describes the rivaroxaban concentration versus time profile for five patients at extremes of 12	
bodyweight with pre-specified mild or no renal impairment and Figure 4f graphically describes four 13	















This is the largest cohort of real-world adult patients used to develop a population PK model for 2	
rivaroxaban. The results demonstrate that in real world clinical practice, rivaroxaban has a  PK profile 3	
consistent with industry studies.[28,35,36]   4	
The primary aim of our study was to address the question of whether bodyweight matters when 5	
rivaroxaban is prescribed at fixed doses. Current ISTH SSC recommendations caution against the use 6	
of rivaroxaban >120kg or BMI >40kg/m2 due to limited efficacy and safety data and concern about 7	
inadequate exposure in this population.  8	
The covariate analysis found CRCL, calculated using CG, with LBW as the weight descriptor in this 9	
equation, to be the most significant covariate. Notably, the univariate analysis did see a significant 10	
reduction of the objective function when bodyweight (LBW or TBW) was added as a covariate to 11	
CL/F. However, renal function was found to be the predominant covariate. Importantly, renal function 12	
is a composite covariate, combining creatinine, a weight descriptor, age and gender. Our data suggest 13	
that CRCL, calculated using CG as a combined covariate, is the single best predictor of rivaroxaban 14	
exposure.   15	
Emerging outcome data are encouraging for rivaroxaban use in morbidly obese patients. The Dresden 16	
NOAC registry investigated the impact of BMI on cardiovascular rates, major bleeding and all-cause 17	
mortality with no association between high BMI and DOAC efficacy or safety.[37] On a larger scale, 18	
a retrospective US database analysis revealed no difference in VTE recurrence between a 1:1 19	
propensity matched, morbidly obese cohort of patients prescribed rivaroxaban or warfarin. 20	
Interestingly, contrary to ISTH recommendations, <1% of those rivaroxaban patients had an anti-Xa 21	
level drawn.[16] Similarly in the US, Peterson and colleagues reported the safety and efficacy of 22	
rivaroxaban prescribed for a 1:1 propensity matched, morbidly obese cohort of patients with AF, 23	






Despite promising outcome data, the pharmacokinetics of rivaroxaban in obesity have not been fully 1	
described until now. Early PK studies in healthy volunteers have previously demonstrated that Cmax 2	
and AUC are unaffected by bodyweight over 120kg.[36] A large pooled PK model, derived across all 3	
indications from 4918 patients in industry-led studies, also showed that bodyweight alone had only a 4	
minor influence on rivaroxaban pharmacokinetics.[28] Barsam and colleagues presented an early 5	
population PK model which also signalled that weight alone was not a significant covariate. However, 6	
this study was limited by the small number of patients >100kg (n=17) or BMI >40kg/m2 (n=6).[20]  7	
We present compelling evidence that high bodyweight has only a minor influence on rivaroxaban 8	
primary PK parameters (Figure 4a).  Our population model includes 86 patients with weight >120kg 9	
and 76 with a BMI >40kg/m2. The highest bodyweight reported in the study was 172kg, rendering our 10	
model well placed to answer the question of whether rivaroxaban PK is influenced by high 11	
bodyweight. Our findings strengthen the argument from early clinical studies in healthy volunteers, 12	
indication specific models, pooled industry data and the summary of product characteristics which 13	
recommend that no dose adjustment is necessary in this population.[28,35,36,38]  14	
Increasingly, the question of bodyweight is also encountered for those with a low bodyweight. This is 15	
an important subgroup as we treat an increasingly ageing population, as well as more patients with 16	
cancer in light of new recommendations for the treatment of cancer associated VTE with 17	
DOACs.[39,40]  As yet, there is no guidance for the management of patients with weight <50 kg.[12]  18	
The concern with low bodyweight is the risk of over anticoagulation. The Einstein investigators had 19	
only a small number of patients (n=167) weighing less than 50kg in their pooled analysis and were 20	
unable to draw meaningful conclusions on safety.[15] Whilst there is only limited outcome data in 21	
this subgroup for rivaroxaban, our study indicates that if renal function is good, then low bodyweight 22	
alone does not justify avoiding rivaroxaban. Our population model included 30 patients with a 23	
bodyweight <50kg, with the lowest bodyweight reported at 39kg. AUC values simulated from the 24	
model suggest that the median AUC is 10% higher in a patient weighing 45kg. Patient weight is 25	






The most significant covariate driving rivaroxaban pharmacokinetics and exposure was CRCLLBW 1	
(Figure 4b). This is not surprising given one third of rivaroxaban is renally excreted as unchanged 2	
drug, whilst the remaining two thirds undergo metabolic degradation via cytochrome P450 3	
(CYP)3A4, CYP2J2 and CYP-independent biotransformation processes. This further highlights the 4	
importance of assessing renal function at initiation and at regular intervals during therapy.  5	
Consideration was given to the method for estimating renal function to be included in the covariate 6	
analysis. CG and estimated glomerular filtration rate (eGFR) were options from the data available. 7	
EGFR was found to be suboptimal in comparison with CG during a preliminary univariate analysis. 8	
For practical reasons, one method of estimating renal function was carried forward for the full 9	
covariate analysis. Consequently, and since it is the preferred method in industry, and clinical 10	
practice, CG was selected. 11	
The selection of LBW rather than TBW in the CG calculation for renal function was based upon the 12	
results of the univariate covariate analysis. LBW improved the objective function by -169.376 13	
compared with the use of TBW by -143.138. The limitations surrounding the use of CG at extremes of 14	
bodyweight has been highlighted for the DOACs previously.[41,42] The concern is that by calculating 15	
CG using TBW, renal function may be over-estimated in obese patients. A surrogate for TBW in the 16	
CG calculation is common for medications with a narrow therapeutic window such as gentamicin to 17	
avoid toxicity. However, no adjustments for weight were made in the calculation of renal function in 18	
the phase III studies for DOACs. Further research in this area is required.	 19	
Where there is concern about under and over anticoagulation, therapeutic drug monitoring (TDM) 20	
could be considered for rivaroxaban in view of its consistent PK profile. At extremes of bodyweight, 21	
the current ISTH recommendation for those prescribed rivaroxaban >40kg/m2 or >120kg is for a peak 22	
and trough plasma concentration to assess adequate exposure.[12] In light of our findings we 23	
recommend, a rivaroxaban plasma concentration for those <50kg in whom there may be concern 24	
regarding accumulation and those >150kg in whom less data exists. A trough sample should be 25	
prioritised, since it is the clearance that is of interest. and assessed according to the expected range 26	





The limitations of this study are that most samples were collected during routine TDM as standard of 1	
care. Furthermore, all patients were assumed to have been adherent and followed dosing instructions 2	
(rivaroxaban should be taken with food) and therefore to have been at steady state at the time of the 3	
sample. The goodness of fit plots show a tendency to underestimate rivaroxaban concentrations at the 4	
higher concentrations, as has been described previously by Willmann and has been attributed to the 5	
sparse data and the use of a one-compartment rather than a two-compartment model.[28]  6	
Importantly, these findings are limited only to rivaroxaban and cannot be extrapolated to the other 7	
DOACs in view of the heterogeneity of DOAC PK profiles. Given weight features in the dosing 8	
guidance for both apixaban (AF) and edoxaban (VTE and AF), further research to determine safety 9	
and efficacy for each of the DOACs at the extremes of bodyweight is required.  10	
To conclusively answer the question of whether rivaroxaban is as safe and as effective as warfarin 11	
across indications at extremes of bodyweight, a large randomised control trial would be required. 12	
However, conducting a prospective analysis of patients weighing <50kg or >120kg, or with a BMI 13	
>40kg/m2 would be challenging. The low event rate for VTE recurrence and major bleeding would 14	
mean large numbers of patients would be required and ultimately they represent small subgroups of 15	
the population as a whole.[46]  16	
Our findings provide further compelling evidence that weight alone is not the most significant factor 17	
influencing rivaroxaban pharmacokinetics. Indeed, at our centre we use rivaroxaban for the acute 18	
treatment of VTE in patients weighing >120kg and weighing <50kg and suggest the ISTH SSC 19	
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